Pembrolizumab in Head and Neck Cancer—Promise and Price
This Viewpoint considers the financial impact of expanding the indication of pembrolizumab for treatment of resectable locally advanced head and neck squamous cell carcinoma expressing programmed cell death 1 ligand 1.
Authors
- Vinay K. Rathi (ORCID: https://orcid.org/0000-0002-9763-9075)
- James William Rocco (ORCID: https://orcid.org/0000-0001-5312-0303)
- Lauren E. Miller (ORCID: https://orcid.org/0000-0002-5458-0544)
Institutions
- Ohio Department of Health (US)
- The Ohio State University (US)
Publication Details
- Journal
- JAMA Otolaryngology–Head & Neck Surgery
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1001/jamaoto.2025.4624
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00